Pfizer Corporation

Enko Chem, Inc.

Paul Galatsis

Travis T Wager

Jaclyn Louise Henderson

Bethany Lyn Kormos

Antonia Friederike Stepan

Ravi G Kurumbail

Patrick Robert Verhoest

Neville J Anthony

Lei Zhang

Matthew Merrill Hayward

Martin Youngjin Pettersson

Michelle Renee Garnsey

Peter Stchur, Iii

David Jeffrey Lauffer

Christopher John Helal

Thomas Allen Chappie

Matthew Richard Reese

Karen Jean Coffman

Luis Angel Martinez-Alsina

Michael Aaron Brodney

Jotham Wadsworth Coe

Joseph Scott Warmus

Yuan Zhang

Jinshan Michael Chen

Colin Richard Rose

The present invention relates to protoporphyrinogen IX oxidase (PPO) inhibitors of the general formula (I) where the variables are defined herein. The invention features processes and intermediates for preparing the compounds of formula (I), compositions comprising them, and their use as herbicides—e.g., for controlling harmful plants. The invention also features methods for controlling unwanted vegetation comprising allowing an herbicidal effective amount of at least one PPO inhibitor of formula (I) to act on plants, their seed, and/or their habitat.

Protoporphyrinogen oxidase inhibitors

The present invention relates to protoporphyrinogen oxidase inhibitors of the general formula (I) where the variables are defined herein. The invention features processes and intermediates for preparing the benzoxazinones of formula (I), compositions comprising them, and their use as herbicides&#x2014;i.e. for controlling harmful plants. The invention also features methods for controlling unwanted vegetation comprising allowing an herbicidal effective amount of at least one benzoxazinone of formula (I) to act on plants, their seed, and/or their habitat.

The present invention provides novel imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof I wherein R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors

The present invention provides novel cyclic substituted imidazo[4,5-c]quinoline derivatives of Formula (I), and the pharmaceutically acceptable salts thereof; wherein R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy. 

Cyclic substituted imidazo[4,5-c]quinoline derivatives

The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R, R, R, R, R, R, R, X and Z are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of Formula (I) and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives as LRRK2 inhibitors

The present invention provides novel 3,4-disubstituted-1H-pyrrolo[2,3-b]pyridine derivatives and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R, R, R, Rand X are as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

3,4-disubstituted-1 H-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7H-pyrrolo[2,3-c]pyridazines as LRRK2 inhibitors

The present invention provides novel 4,5-disubstituted-7H-pyrrolo[2,3-d]pyrimidine derivatives of Formula I, and the pharmaceutically acceptable salts thereof wherein R, R, R, Rand Rare as defined in the specification. The invention is also directed to pharmaceutical compositions comprising the compounds of formula I and to use of the compounds in the treatment of diseases associated with LRRK2, such as neurodegenerative diseases including Parkinson's disease or Alzheimer's disease, cancer, Crohn's disease or leprosy.

Substituted pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors

4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Growing community of inventors

Newton, MA, United States of America

Paul Galatsis